Free Trial
NASDAQ:ENGN

enGene Q2 2024 Earnings Report

enGene logo
$3.68 +0.11 (+3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 +0.07 (+2.04%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Friday, June 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

enGene's Q3 2025 earnings is scheduled for Wednesday, September 10, 2025, with a conference call scheduled on Tuesday, September 9, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Earnings Headlines

Green Light for These Stocks
Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

View enGene Profile

More Earnings Resources from MarketBeat